MEDNAX (MD) Misses Q4 EPS by 2c

MEDNAX (NYSE: MD) reported Q4 EPS of $0.47, $0.02 worse than the analyst estimate of $0.49. Revenue for the quarter came in at $514 million versus the consensus estimate of $501.23 million.

GUIDANCE:

On a preliminary basis, Pediatrix anticipates that its 2023 Adjusted EBITDA, as defined above, will be in a range of $235 million to $245 million. This outlook does not reflect any additional funds from the provider relief fund established by the CARES Act, which favorably impacted Adjusted EBITDA by approximately $6.7 million for the year ended December 31, 2022.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance